dc.contributor.author | Gallego, S | |
dc.contributor.author | Chi, Y-Y | |
dc.contributor.author | De Salvo, GL | |
dc.contributor.author | Li, M | |
dc.contributor.author | Merks, JHM | |
dc.contributor.author | Rodeberg, DA | |
dc.contributor.author | van Scheltinga, ST | |
dc.contributor.author | Mascarenhas, L | |
dc.contributor.author | Orbach, D | |
dc.contributor.author | Jenney, M | |
dc.contributor.author | Million, L | |
dc.contributor.author | Minard-Colin, V | |
dc.contributor.author | Wolden, S | |
dc.contributor.author | Zanetti, I | |
dc.contributor.author | Parham, DM | |
dc.contributor.author | Mandeville, H | |
dc.contributor.author | Venkatramani, R | |
dc.contributor.author | Bisogno, G | |
dc.contributor.author | Hawkins, DS | |
dc.contributor.author | European paediatric Soft tissue sarcoma Study Group and Children's Oncology Group | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2024-04-30T15:55:03Z | |
dc.date.available | 2024-04-30T15:55:03Z | |
dc.date.issued | 2021-03-01 | |
dc.identifier | ARTN e28832 | |
dc.identifier.citation | Pediatric Blood and Cancer, 2021, 68 (3), pp. e28832 - | |
dc.identifier.issn | 1545-5009 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6213 | |
dc.identifier.eissn | 1545-5017 | |
dc.identifier.eissn | 1545-5017 | |
dc.identifier.doi | 10.1002/pbc.28832 | |
dc.identifier.doi | 10.1002/pbc.28832 | |
dc.description.abstract | BACKGROUND: Treatment of children and adolescents with alveolar rhabdomyosarcoma (ARMS) and regional nodal involvement (N1) have been approached differently by North American and European cooperative groups. In order to define a better therapeutic strategy, we analyzed two studies conducted between 2005 and 2016 by the European paediatric Soft tissue sarcoma Study Group (EpSSG) and Children's Oncology Group (COG). METHODS: We retrospectively identified patients with ARMS N1 enrolled in either EpSSG RMS2005 or in COG ARST0531. Chemotherapy in RMS2005 comprised ifosfamide + vincristine + dactinomycin + doxorubicin (IVADo), IVA and maintenance (vinorelbine, cyclophosphamide); in ARST0531, it consisted of either vincristine + dactinomycin + cyclophosphamide (VAC) or VAC alternating with vincristine + irinotecan (VI). Local treatment was similar in both protocols. RESULTS: The analysis of the clinical characteristics of 239 patients showed some differences between study groups: in RMS2005, advanced Intergroup Rhabdomyosarcoma Study Group (IRS) and large tumors predominated. There were no differences in outcomes between the two groups: 5-year event-free survival (EFS), 49% (95% confidence interval [CI]: 39-59) and 44% (95% CI: 30-58), and overall survival (OS), 51% (95% CI: 41-61) and 53.6% (95% CI: 40-68) in RMS2005 and ARST0531, respectively. In RMS2005, EFS of patients with FOXO1-positive tumors was significantly inferior to those with FOXO1-negative (49.3% vs 73%, P = .034). In contrast, in ARST0531, EFS of patients with FOXO1-positive tumors was 45% compared with 43.8% for those with FOXO1-negative. CONCLUSIONS: The outcome of patients with ARMS N1 was similar in both protocols. However, patients with FOXO1 fusion-negative tumors enrolled in RMS2005 showed a significantly better outcome, suggesting that different strategies of chemotherapy may have an impact in the outcome of this subgroup of patients. | |
dc.format | Print-Electronic | |
dc.format.extent | e28832 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | WILEY | |
dc.relation.ispartof | Pediatric Blood and Cancer | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | alveolar rhabdomyosarcoma | |
dc.subject | chemotherapy | |
dc.subject | nodal involvement | |
dc.subject | prognostic factors | |
dc.subject | rhabdomyosarcoma | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Child | |
dc.subject | Child, Preschool | |
dc.subject | Female | |
dc.subject | Follow-Up Studies | |
dc.subject | Humans | |
dc.subject | Infant | |
dc.subject | Infant, Newborn | |
dc.subject | Lymph Nodes | |
dc.subject | Male | |
dc.subject | Prognosis | |
dc.subject | Retrospective Studies | |
dc.subject | Rhabdomyosarcoma, Alveolar | |
dc.subject | Survival Rate | |
dc.title | Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-11-08 | |
dc.date.updated | 2024-04-16T14:46:24Z | |
rioxxterms.version | AM | |
rioxxterms.versionofrecord | 10.1002/pbc.28832 | |
rioxxterms.licenseref.startdate | 2021-03-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/33245207 | |
pubs.issue | 3 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Paediatric and Adolescent Radiotherapy | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1002/pbc.28832 | |
pubs.volume | 68 | |
icr.researchteam | Paed & Adolesc Radiother | |
dc.contributor.icrauthor | Mandeville, Henry | |
icr.provenance | Deposited by Henry Mandeville on 2024-04-16. Deposit type is initial. No. of files: 1. Files: Alveolar rhabdomyosarcoma with regional nodal involvement Results of a combined analysis from two cooperative groups.pdf | |